DrugBiological
Alemtuzumab clinical trials
Also written Campath-1H, Lemtrada and LDP-03.
- studies test it
- 222
- open now
- 13
- in phase 3
- 16
- first study started
- 1999
Keep track of what changes. Save the Alemtuzumab studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Name
- Alemtuzumab
- 171
- Campath
- 65
Brand
- Lemtrada
- 15
Development codes
Other names
Combined with it in one product
Studies by the year they started
221 studies that test it; most in 2005 (27)
| Year | Studies |
|---|---|
| 1999 | 1 |
| 2000 | 8 |
| 2001 | 10 |
| 2002 | 17 |
| 2003 | 21 |
| 2004 | 17 |
| 2005 | 27 |
| 2006 | 20 |
| 2007 | 19 |
| 2008 | 11 |
| 2009 | 9 |
| 2010 | 4 |
| 2011 | 12 |
| 2012 | 7 |
| 2014 | 4 |
| 2015 | 5 |
| 2016 | 1 |
| 2017 | 7 |
| 2018 | 8 |
| 2019 | 3 |
| 2020 | 2 |
| 2022 | 2 |
| 2023 | 1 |
| 2024 | 1 |
| 2025 | 1 |
| 2026 | 3 |
By phase
A phase 1/2 study counts in both.
- Early Phase 1
- 5
- Phase 1
- 59
- Phase 2
- 153
- Phase 3
- 16
- Phase 4
- 14
- No phase
- 15
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 18 · Other 204
Baylor College of Medicine (16) · M.D. Anderson Cancer Center (13) · Genzyme, a Sanofi Company (13) · National Heart, Lung, and Blood Institute (NHLBI) (11) · Masonic Cancer Center, University of Minnesota (10) · National Institute of Allergy and Infectious Diseases (NIAID) (9) · National Cancer Institute (NCI) (9) · Northwestern University (7)
Often tested with
Tested in the same studies.
Fludarabine (50) · Cyclophosphamide (36) · Rituximab (25) · Busulfan (23) · Sirolimus (20) · Melphalan (18) · Fludarabine phosphate (15) · Cyclosporine (14)
Studies
Open first, then newest update. How each study uses Alemtuzumab is read from its arms, and is right about nine times in ten.
Testing it · 222
- Partial Stem Cell Transplant for Sickle Cell Disease From Matched DonorsRecruitingPhase 1/2National Heart, Lung, and Blood Institute (NHLBI)NCT07599176Written as Alemtuzumab
- Intestinal & Multivisceral Transplantation for Unresectable Mucinous Carcinoma Peritonei (TRANSCAPE)Not yet recruitingPhase 2Case Comprehensive Cancer CenterNCT06084780Written as Alemtuzumab
- Autologous Stem Cell Transplantation in Patients With Systemic SclerosisRecruitingPhase 2Paul SzabolcsNCT03630211Written as Alemtuzumab
- T-Cell Depleted Alternative Donor Bone Marrow Transplant for Sickle Cell Disease (SCD) and Other AnemiasRecruitingPhase 1/2Paul SzabolcsNCT03653338Written as Alemtuzumab
- Base Editing for Mutation Repair in Hematopoietic Stem & Progenitor Cells for X-Linked Chronic Granulomatous DiseaseRecruitingPhase 1/2National Institute of Allergy and Infectious Diseases (NIAID)NCT06325709Written as Campath
- Base Editing Hematopoietic Stem Cell and T Cell Gene Therapy for CD40L-HyperIgM Syndrome: Single Patient StudyRecruitingPhase 1/2National Institute of Allergy and Infectious Diseases (NIAID)NCT06959771Written as Alemtuzumab
- Haploidentical Donor Hematopoietic Cell Transplant for Sickle Cell DiseaseRecruitingPhase 2St. Jude Children's Research HospitalNCT07616154Written as Alemtuzumab
- Precision Alemtuzumab Dosing for Allogeneic Hematopoietic Cell TransplantationRecruitingPhase 2Children's Hospital Medical Center, CincinnatiNCT05501756Written as Alemtuzumab
- Nonmyeloablative Stem Cell Transplant in Children With Sickle Cell Disease and a Major ABO-Incompatible Matched Sibling DonorRecruitingPhase 2University of CalgaryNCT03214354Written as Alemtuzumab
- Minimizing Toxicity in HLA-identical Sibling Donor Transplantation for Children With Sickle Cell DiseaseRecruitingPhase 2Robert NickelNCT03587272Written as Alemtuzumab, low dose total body irradiation, Sirolimus
- Alpha/Beta TCD HCT in Patients With Inherited BMF DisordersRecruitingPhase 2Masonic Cancer Center, University of MinnesotaNCT03579875Written as Alemtuzumab
- Lung and Bone Marrow Transplantation for Lung and Bone Marrow FailureRecruitingPhase 1/2Paul SzabolcsNCT03500731Written as Alemtuzumab
- Reduced Intensity Conditioning for Non-Malignant Disorders Undergoing UCBT, BMT or PBSCTRecruitingPhase 2Paul SzabolcsNCT01962415Written as Alemtuzumab
- High Dose Peripheral Blood Stem Cell Transplantation With Post Transplant Cyclophosphamide for Patients With Chronic Granulomatous DiseaseActive, not recruitingPhase 1/2National Institute of Allergy and Infectious Diseases (NIAID)NCT02629120Written as Alemtuzumab
- Haploidentical Transplant for People With Chronic Granulomatous Disease (CGD) Using Alemtuzumab, Busulfan and TBI With Post-Transplant CyclophosphamideActive, not recruitingEarly Phase 1National Institute of Allergy and Infectious Diseases (NIAID)NCT03910452Written as Alemtuzumab
- Early Human Leukocyte Antigen (HLA) Matched Sibling Hematopoietic Stem Cell TransplantationActive, not recruitingPhase 2Emory UniversityNCT04018937Written as Alemtuzumab
- Optimization of NULOJIX® Usage As A Means of Avoiding CNI and Steroids in Renal TransplantationTerminatedPhase 2National Institute of Allergy and Infectious Diseases (NIAID)NCT01436305Written as Alemtuzumab
- Improving the Results of Bone Marrow Transplantation for Patients With Severe Congenital AnemiasActive, not recruitingPhase 1/2National Heart, Lung, and Blood Institute (NHLBI)NCT00061568Written as Alemtuzumab
- Reduced Intensity Transplantation for Severe Sickle Cell DiseaseActive, not recruitingPhase 2St. Jude Children's Research HospitalNCT04362293Written as hydroxyurea, azathioprine, alemtuzumab, thiotepa, plerixafor, low dose total body irradiation, cyclophosphamide and sirolimus
- Nonmyeloablative Peripheral Blood Mobilized Hematopoietic Precursor Cell Transplantation for Sickle Cell Disease and Beta-thalassemia in People With Higher Risk of Transplant FailureActive, not recruitingPhase 2National Heart, Lung, and Blood Institute (NHLBI)NCT02105766Written as Alemtuzumab
See all 222 studies that test Alemtuzumab →
Given in every arm · 41 — Alemtuzumab is usual care beside what is tested
- Allogeneic Hematopoietic Stem Cell Transplant for Patients With Inborn Errors of ImmunityRecruitingPhase 2National Cancer Institute (NCI)NCT04339777Written as Alemtuzumab
- Allogeneic Hematopoietic Stem Cell Transplantation for Chronic Granulomatous Disease (CGD) With an Alemtuzumab, Busulfan and TBI-based Conditioning Regimen Combined With Cytokine (IL-6, +/- IFN-gamma) AntagonistsRecruitingPhase 1/2National Institute of Allergy and Infectious Diseases (NIAID)NCT05463133Written as Alemtuzumab
- 131I-apamistamab-based Conditioning for Hematopoietic Stem Cell Transplant (HSCT) in Advanced Sickle Cell Disease (SCD)RecruitingPhase 1Columbia UniversityNCT07015684Written as Campath
- Allo HSCT for High Risk HemoglobinopathiesRecruitingPhase 2Masonic Cancer Center, University of MinnesotaNCT06872333Written as Alemtuzumab
- Autologous Stem Cell Transplantation for Crohn's DiseaseRecruitingPhase 1/2Paul SzabolcsNCT00692939Written as Alemtuzumab
- Regenerative Medicine to Restore Hematopoiesis and Immune Function in Immunodeficiencies and Inherited Bone Marrow FailuresRecruitingPhase 2Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsNCT04232085Written as Alemtuzumab
- Sickle Cell Disease Transplant Using a Nonmyeloablative Approach for Patients With Anti-donor Red Cell AntibodyRecruitingPhase 2Children's National Research InstituteNCT06358638Written as Alemtuzumab
- Phase 1/2 Study of UCART22 in Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia (BALLI-01)RecruitingPhase 1/2Cellectis S.A.NCT04150497Written as CLLS52
- Study Evaluating UCART20x22 in B-Cell Non-Hodgkin LymphomaRecruitingPhase 1/2Cellectis S.A.NCT05607420Written as CLLS52
- A Comparison of Reduced Dose Total Body Irradiation (TBI) and Cyclophosphamide With Fludarabine and Melphalan Reduced Intensity Conditioning in Adults With Acute Lymphoblastic Leukaemia (ALL) in Complete Remission. (ALL-RIC)Active, not recruitingPhase 2University of BirminghamNCT03821610Written as Alemtuzumab
- Haploidentical PBMC Transplant for Severe Congenital AnemiasActive, not recruitingPhase 1/2National Heart, Lung, and Blood Institute (NHLBI)NCT00977691Written as Alemtuzumab
- Sequential Targeting of Cluster of Differentiation 52 (CD52) and Tumor Necrosis Factor (TNF) Allows Early Minimization Therapy in Kidney TransplantationCompletedNot applicableInstitute for Clinical and Experimental MedicineNCT02711202Written as MabCampath,
- A Study of CD45RA+ Depleted Haploidentical Stem Cell Transplantation in Children With Relapsed or Refractory Solid Tumors and LymphomasCompletedPhase 1St. Jude Children's Research HospitalNCT01625351Written as alemtuzumab
- Hematopoietic Stem Cell Transplant for Dyskeratosis Congenita or Severe Aplastic AnemiaCompletedNot applicableMasonic Cancer Center, University of MinnesotaNCT02162420Written as Alemtuzumab
- Stem Cell Mobilization (Plerixafor) and Immunologic Reset in Type 1 Diabetes (T1DM)CompletedPhase 1/2University of AlbertaNCT03182426Written as Alemtuzumab
- Abatacept for GVHD Prophylaxis After Hematopoietic Stem Cell Transplantation for Pediatric Sickle Cell DiseaseCompletedPhase 1Monica BhatiaNCT02867800Written as Alemtuzumab
- CD34+ (Malignant) Stem Cell Selection for Patients Receiving Allogenic Stem Cell TransplantActive, not recruitingPhase 1/2Diane GeorgeNCT02061800Written as Alemtuzumab
- Alemtuzumab or Tocilizumab in Combination With Etoposide and Dexamethasone for the Treatment of Adult Patients With Hemophagocytic LymphohistiocytosisCompletedPhase 2M.D. Anderson Cancer CenterNCT02385110Written as Alemtuzumab
- Dasatinib Followed by Stem Cell Transplant in Treating Older Patients With Newly Diagnosed Acute Lymphoblastic LeukemiaCompletedPhase 2National Cancer Institute (NCI)NCT01256398Written as Alemtuzumab
- Treatment of Relapsed T-cell Acute Lymphoblastic Leukemia or T-lymphoblastic Lymphoma With MabCampathCompletedPhase 2Goethe UniversityNCT00199030Written as Alemtuzumab (MabCampath)
Showing 20 of 41.
As the comparator · 6 — what is tested is compared with Alemtuzumab
- Randomized Autologous heMatopoietic Stem Cell Transplantation Versus Alemtuzumab, Cladribine or Ocrelizumab for RRMS (RAM-MS)Active, not recruitingPhase 3Haukeland University HospitalNCT03477500Written as Alemtuzumab
- Risk-Adapted Allogeneic Stem Cell Transplantation For Mixed Donor Chimerism In Patients With Non-Malignant DiseasesCompletedPhase 2/3Columbia UniversityNCT01019876Written as Alemtuzumab
- Ocrelizumab or Alemtuzumab Compared With Autologous Hematopoietic Stem Cell Transplantation in Multiple Sclerosis - a Phase-2 Randomised Controlled TrialTerminatedPhase 2Universitätsklinikum Hamburg-EppendorfNCT04971005Written as Alemtuzumab
- CamTac Trial:Campath-Tacrolimus vs IL2R MoAb/Tacrolimus/MMF in Renal TransplantationCompletedPhase 4EMagnussonNCT00246129Written as Campath
- SCH 727965 in Patients With Mantle Cell Lymphoma or B-Cell Chronic Lymphocytic Leukemia (Study P04715)TerminatedPhase 2Merck Sharp & Dohme LLCNCT00871546Written as Alemtuzumab
- Fludarabine, Cyclophosphamide, and Rituximab or Alemtuzumab in Treating CLL2007 CLL 2007 FMPCompletedPhase 3French Innovative Leukemia OrganisationNCT00564512Written as Campath
Codes
What other systems call Alemtuzumab · ClinicalTrials.gg INT006639
- MeSH (NLM) D000074323AlemtuzumabConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) 3A189DH42VALEMTUZUMABConfirmed FDA, NLM, Wikidata
- RxNorm 117055Confirmed FDA, Wikidata
- Wikidata Q420164alemtuzumabConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C1681AlemtuzumabOne source FDA
- DrugBank DB00087One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | D000074323 | Alemtuzumab | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | 3A189DH42V | ALEMTUZUMAB | Confirmed FDA, NLM, Wikidata |
| RxNorm | 117055 | — | Confirmed FDA, Wikidata |
| Wikidata | Q420164 | alemtuzumab | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C1681 | Alemtuzumab | One source FDA |
| DrugBank | DB00087 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.